Hence, anti-HER2 therapy, which is already in clinical routine for breast cancer patients, clearly demonstrated the power of molecular analysis and targeting of CTCs in the control of metastatic disease and is very encouraging. The gene discussed is ERBB2; the disease is breast carcinoma.